期刊文献+

罗格列酮对体外培养小鼠前成骨细胞系MC3T3-E1生长与分化的影响研究 被引量:1

Effects of Rosiglitazone on Proliferation and Differentiation of Preosteoblast MC3T3-E1 Cell of Mice in Vitro
原文传递
导出
摘要 目的:研究罗格列酮对体外培养小鼠前成骨细胞系MC3T3-E1生长与分化的影响。方法:以小鼠MC3T3-E1作为药物筛选的细胞模型,分别加入1、2、5、10μmo·lL-1罗格列酮干预,MTT法测定细胞活性并计算生长抑制率;流式细胞术检测细胞凋亡率;免疫组化法分析细胞中促凋亡因子Bax和抗凋亡因子Bcl-2蛋白的表达;测定细胞中分化指标碱性磷酸酶(ALP)的活性。设立只加入培养基处理的空白对照组。结果:与空白对照组比较,罗格列酮各浓度组生长抑制率、细胞凋亡率升高(P均<0.05),Bax表达增强、Bcl-2表达减弱、ALP活性下降(P均<0.05),且呈浓度依赖性。结论:罗格列酮可抑制MC3T3-E1细胞生长及分化,并诱导其凋亡;而Bax/Bcl-2可能参与凋亡的发生,并可能起关键调控作用。 OBJECTIVE: To study the effects of rosiglitazone on proliferation and differentiation of preosteoblast MC3T3-E1 cell of mice in vitro. METHODS: MC3T3-E1 cells were treated with 1, 2, 5, 10 μmol·L-1 rosiglitazone. Cell viability was measured by MTT to calculate growth inhibition rate. Cell apoptosis were inspected with flow cytometry, and the expressions of Bax and Bcl-2 were examined by immuno-chemical staining. And the activity of ALP was detected by alkaline phosphatase assay. MC3T3-E1 cells were only cultivated by culture media as blank control group. RESULTS: Compared with blank control group, the growth inhibition rate and apoptosis rate of rosiglitazone groups increased significantly (P〈0.05), and Bax expression was attenuated while Bcl-2 expression and ALP activity decreased (P〈0.05) in dose-dependent manner. CONCLUSION: Rosiglitazone can inhibit the proliferation and differentiation of MC3T3-EI cell, promote apoptosis of MC3T3-E1 eell. Bax/Bcl-2 may be associated with the occurrence of apoptosis and play major regulation effect.
作者 王敏
出处 《中国药房》 CAS CSCD 北大核心 2011年第37期3486-3488,共3页 China Pharmacy
关键词 罗格列酮 前成骨细胞系MC3T3-E1 生长 凋亡 分化 Rosiglitazone Preosteoblast MC3T3-E1 Growth Apoptosis Differentiation
  • 相关文献

参考文献16

  • 1康新,李焕德.罗格列酮药代动力学及临床应用研究进展[J].中国临床药理学杂志,2005,21(2):158-160. 被引量:5
  • 2Li M, Pan LC, Simmon HA, et al. Surface -specific eff- ects of a PPARγ agonist, darglitazone, on bone in mice [J]. Bone, 2006, 39(4):796.
  • 3Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral densi- ty in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo- controlled trial[J]. J Clin Endocrinol Metab, 2008, 93(5) : 1 696.
  • 4Kahn SE, Haffner SM, Heise MA, et al. Glycemic dura- bility of rosiglitazone, metformin, or glyburide monother- apy[J].NEngl J Med, 2006,335 (23) : 2 427.
  • 5All AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differ- entiation and bone formation[J]. Endocrinology, 2005,146 (3):1 226.
  • 6Sudo H, Kodama HA, Amagai Y, et aL In vitro differen- tiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria[J]. J Cell Biol, 1983, 96(1):191.
  • 7Lim SY, Jang JH, Na HK, et al. 15-Deoxy-Delta 12,14- prostaglandin J (2) protects against nitrosative PC12 cell death through up-regulation of intracellular glutathione synthesis[J]. J Biol Chem, 2004,279(44) :46 263.
  • 8Jackson SM, Demer LL. Peroxisome proliferator-activat- ed receptor activators modulate the esteoblastic matura- tion of MC3T3-E1 preosteoblasts[J]. FEBS Letters, 2000, 471(1):119.
  • 9Jung JY, Yoo CI, Kim HT, et al. Role ofmitogen-activat- ed protein kinase (MAPK) in troglitazone-induced osteo- blastic cell death[J]. Toxicology, 2007, 234(1-2) : 73.
  • 10Kahn SE, Zinman B, Lachin IM, et al. Rosiglitazone-as- sociated fracture in type 2 diabetes : an analysis from a di- abetes outcome progression trial[J]. Diabetes Care, 2008, 31(5) :845.

二级参考文献23

  • 1Hop CE, Tiller PR, Romanyshyn L. In vitro metabolite identification using fast gradient high performance liquid chromatography combined with tandem mass spectrometry [ J ]. Rapid Commun Mass Spectrom,2002; 16:212 -219.
  • 2Lin Z J, Desai - Krieger D, Shum L. Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography - tandem mass spectrometry [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2004 ;801:265 - 272.
  • 3Werner AL, Travaglini MT. A review of rosig litazone in type 2 diabetes mellitus[ J]. Pharmacotherapy, 2001 ;21:1082 - 1099.
  • 4Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food [ J ]. Eur J Clin Pharmacol, 1999 ;55:53 - 56.
  • 5Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer,in humans[J]. Drug Metab Dispos ,2000 ;28 : 772 -780.
  • 6Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone[ J]. Br J Clin Pharmacol , 1999 ;48:424 - 32.
  • 7Miller AK, Inglis AL, Thompson K, et al. Effects of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG) [J]. Clin Pharmacol Ther , 1999 ;65:186.
  • 8Chapelsky MC, Thompson K, Miller A, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency [ J ].J Clin Pharmacol, 2003 ;43: 252 - 259.
  • 9Thompson K, Zussman B, Miller A,et al. Pharmacokinetics of rosiglitazone in patients with end - stage renal disease [ J ]. J Int Med Res,2002 ;30:391 - 399.
  • 10Phillips LS, Grunberger G, Miller E, et al. Once - and twice - daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [ J ]. Diabetes Care,2001 ;24: 308 - 315.

共引文献4

同被引文献10

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部